MedTrace Logo

Radiation and Adebrelimab in Prostate Cancer With Imaging-measurable Disease (RAPID)

NCT06251492 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2024-02-20

No results posted yet for this study

Summary

The aim of this study is to evaluate the efficacy of 2 cycles of combinatory adebrelimab and stereotactic radiotherapy, followed by monotherapy adebrelimab in patients with metastatic castration-resistant prostate cancer. Dr. Yao Zhu from Fudan University Shanghai Cancer Center is the co-leading PI of this study.

Conditions

  • Prostate Cancer Metastatic
  • Castration-resistant Prostate Cancer

Interventions

RADIATION

Stereotactic body radiotherapy

8 Gray x 3 for 2 cycles

DRUG

Adebrelimab

Adebrelimab 20mg/kg IV Q3W for 2 cycles, then Adebrelimab 20mg/kg IV alone Q3W until progression

Sponsors & Collaborators

  • Fudan University

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-01-30
Primary Completion
2025-07-30
Completion
2025-12-30

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06251492 on ClinicalTrials.gov